GoDaddy, Boeing, Moderna and extra

GoDaddy logo

SOPA pictures | LightRakete | Getty Images

Check out the companies that are making headlines in midday trading.

Go Daddy The web hosting company’s shares rose 8.4% after the Wall Street Journal reported that activist investor Starboard Value acquired a 6.5% stake worth approximately $ 800 million.

Delta Airlines – Airlines’ shares fell but bounced back from their lows the following Monday Thousands of flights canceled over the holiday weekend in the midst of staff shortages. Delta was down 0.8%, United was down 0.7%, and American Airlines shares were also trading 0.5% lower. More than 2,000 flights were canceled from Christmas Eve to Sunday evening. The airlines cited the spread of the Omicron Covid variant among the crews as the reason for the cancellations, with bad weather also having an impact on the flights.

Norwegian Cruise Line, royal caribbean – Cruise ship stocks also fell after Covid. was reported Outbreaks on ships. Royal Caribbean lost 1.4%. Carnival was down 1.2%, and Norwegian Cruise Line down by 2.6%.

Las Vegas Sands, MGM resorts Casino operator stocks were sold at the same time as the Omicron variant dampened demand for travel and leisure. Las Vegas Sands lost 1.9%. Wynn Resorts lost 1.5% and MGM Resorts lost 1.2%.

APA Corp., Devonian energy – Energy stocks rose as oil prices rose. APA Corp was up 7.3%, Devon Energy was up 6.1% and Diamondback Energy was up 4.9%.

Modern – Moderna shares gave up after Financial Times reports The drug maker is fighting a shareholder proposal that the company should open up its vaccine technology to poorer countries. The proposal calls on Moderna to explain why its prices are so high given the amount of government financial support it has received.

Didi Global – The shares of Chinese rideshare company Didi fell 5.4% after the Financial Times reported that Didi has been preventing employees from selling company shares for an indefinite period of time. This follows a move by the company earlier this month delist the stock in the United States.

Ralph Lauren, american eagle – Retail stocks rose Monday after early Christmas shopping sales were shown heavy consumption in recent weeks. Ralph Lauren’s shares rose 4.3% while American Eagle’s shares rose 3.5%

– CNBC’s Jesse Pound, Tanaya Macheel, Pippa Stevens and Yun Li contributed to the coverage

CDC panel recommends Pfizer, Moderna vaccines over J&J attributable to uncommon blood clot circumstances

A health care worker holds a dose of the Johnson & Johnson vaccine.

Phill Magakoe | AFP | Getty Images

An advisory board for the Centers for Disease Control and Prevention on Thursday recommended Pfizer and Modern‘s vaccines over Johnson & Johnson‘s shot for adults ages 18 and up after dozens of people found a rare blood clot after the J&J vaccination, all of whom were hospitalized and nine of them died.

The Advisory Committee on Immunization Practices has unanimously decided to recommend Pfizer and Moderna over the Johnson & Johnson vaccine. CDC director Rochelle Walensky has yet to accept the recommendation.

The CDC has confirmed 54 cases of people who develop blood clots and have low blood platelet levels, a new condition known as thrombosis with thrombocytopenia syndrome that mainly affects younger women. All patients were hospitalized, nine people died and 36 were treated in the intensive care unit.

The US has administered more than 17 million J&J doses since the Food and Drug Administration approved the emergency syringe in February.

“TTS case reporting rates after Janssen vaccines are higher in men and women in a wider age range than previous estimates,” said Dr. Keipp Talbot, chairman of the CDC’s vaccines and safety subgroup, the advisory body.

Although the panel’s recommendation was unanimous, some members struggled with the vote. The CDC experts could also have recommended giving up the shot altogether or restricting it to certain age or demographic groups.

Dr. Pablo Sanchez, a professor of pediatrics at Ohio State University, said he was not recommending J&J admission to any of his patients, despite ultimately standing for the panel’s proposal.

“I just can’t recommend a vaccine associated with a disease that can lead to death,” Sanchez told the committee. “I don’t recommend it to any of my patients’ parents.”

Seven of the patients who died were women and two men, with a mean age of 45 years. Most of the deceased had previous health conditions such as obesity, high blood pressure and diabetes. The death reporting rate was 0.57 deaths per million doses administered, according to the CDC.

“In reviewing these cases, we noticed how quickly patient status deteriorates and leads to death,” said Dr. Isaac See of the CDC’s Vaccine Safety Team joined the advisory board.

According to the CDC, patients typically developed symptoms 9 days after vaccination and were hospitalized 5 days after symptoms appeared. The overwhelming majority of patients were women, 37 total, and the mean age was 44. Seventeen men developed TTS.

Johnson & Johnson’s director of global therapeutic vaccines Penny Heaton defended the company’s shot during the meeting, saying it “saves lives here in the US and on every continent around the world”.

“It’s easy to store and transport,” said Heaton. “In many low- and middle-income countries, our vaccine is the primary and sometimes even the only option in the US as its permanent protection may be the preferred choice for people who cannot or do not want to return for multiple vaccinations.”

Heaton said J&J recognizes the incidents of TTS related to the vaccine and that the condition can be fatal, although cases are rare. She said patient safety and wellbeing remain a top priority for J&J, and the company has several studies underway to identify risk factors related to developing TTS.

In April, the Food and Drug Administration and the CDC stopped briefly the use of the Johnson & Johnson single vaccine after six adult women developed blood clots and low platelet counts at the same time.

A week later, the FDA and the CDC did canceled the break on J&J shots after the independent advisory panel said the benefits of the shots outweigh the risks. At the time, the panel did not recommend restricting admissions based on age or gender. It suggested that the FDA put a warning label on for women under 50.

The FDA has advised health care providers not to give a J&J booster to people who have developed TTS in the past after the first injection. The FDA also said the J&J syringe should not be given to people who received the vaccine from AstraZeneca, even though AstraZeneca is not approved for use in the United States

CDC experts said Thursday that people who received J&J booster doses have not seen any cases of TTS, although the number of boosters is relatively small.

“Currently available evidence supports a causal relationship between TTS and the Janssen COVID-19 vaccine,” the FDA said in the factsheet for healthcare providers.

In October, the FDA and CDC approved authorized J&J boosters for all adults at least two months after receiving their first J&J syringe. More than 800,000 people have received J&J boosters, according to CDC data. People who received their primary vaccination with the J&J shot can also be boosted with the Pfizer or Moderna vaccines.

This is the latest news. Please check again for updates.

American Airways, Hole, Moderna and extra

An American Airlines aircraft lands at Ronald Reagan Washington National Airport in Arlington, Virginia on November 23, 2021.

Drew Angerer | Getty Images

Check out the companies that hit the headlines on Tuesday at noon.

American Airlines, Norwegian Cruise Line Travel stocks fell as investors continued to weigh the risks of the Covid-Omicron variant. American Airlines shares were down more than 4%, Norwegian Cruise Line was down more than 6%, Wynn Resorts was down around 5%, and Airbnb was down 4.9%.

gap, Under armor Retail stocks have come under pressure after online sales fell 1.4% year over year on Cyber ​​Monday and fell for the first time ever, according to Adobe Analytics. However, Adobe expects customers to expand their shopping this year and expects the entire holiday season to see record-breaking online sales growth. Gap down more than 6%, Under Armor down about 5%, and Tommy Hilfiger parents PVH Corp lost more than 4%.

Regeneron Pharma – Regeneron’s shares fell more than 2% after the company owned its Covid-19 antibody drugs could be less effective against the omicron variant of Covid. The company said mutations in the variant suggest that “the neutralizing activity of both vaccine-induced and monoclonal antibody-mediated immunity may be reduced”.

Modern, Pfizer Vaccine manufacturer stocks were in focus after Moderna CEO Stephane Bancel told the Financial Times that he was expects existing vaccines to be less effective against the Omicron variant. Researchers are still studying the new variant’s response to previous immunity, and Oxford University said it was no evidence yet that current vaccines do not protect against serious Omicron disease. The Moderna share lost more than 6%. The BioNTech share fell by more than 5%. Pfizer stock gained around 2%. Novavax shares gained more than 2%.

Money tree – The discounter’s stock slumped 4.5% after Goldman Sachs downgraded Dollar Tree too neutral of buy. The company said the company’s operational improvements have been priced in and Dollar Tree will face pedestrian traffic issues in the coming year.

Solar drain – The stock of clean energy lost 6.3% Morgan Stanley downgraded it balanced. The investment firm issued a notice to its clients that Solaredge’s shares may be fully valued after a recent hot spell.

Meta platforms Facebook parent Meta shares fell more than 3% after UK competition watchdog said the company should sell the GIF sharing platform Giphy, which Facebook acquired last year. The regulator said the deal could harm social media users and UK advertisers. Meta has stated that she does not agree with the decision and is considering an appeal.

Beyond meat, oatmeal Beyond Meat and Oatly stocks fell approximately 6% and 7% respectively after HSBC began coverage of protein stocks with a downgraded rating. “Given the prospect of increased competition, the growth we forecast will not be enough for many participants to meet their high growth ambitions,” the company said.

Twitter, square – Twitter and Square shares fell more than 5% and 2%, respectively. The moves come a day later Jack Dorsey has announced his resignation as CEO of Twitter while he remained at Square as chief executive. Bank of America upgraded Place to neutral of below average performance and repeat a purchase review for Twitter.

– CNBC’s Jesse Pound and Tanaya Macheel contributed to the coverage

Pfizer-BioNTech, Moderna, J&J, AstraZeneca investigating omicron

The world’s largest manufacturers of Covid-19 vaccines announced on Friday that they were working to rapidly screen their vaccines and adapt them to a new and highly mutated strain of the virus.

The World Health Organization said Friday the new strain, dubbed Omicron, is a “worrying variant” that could pose a higher risk of reinfection than previous mutations of the virus.

Pfizer and BioNTech said they are studying Omicron, labeled B.1.1.529 first, and can quickly adjust their vaccine if necessary.

“We understand the concerns of experts and immediately initiated investigations into variant B.1.1.529,” said the company.

Pfizer and BioNTech expect further data from laboratory tests in two weeks at the latest.

“These data will provide more information on whether B.1.1.529 could be an escape variant that could require our vaccine to be modified if the variant spreads globally,” the companies said.

Pfizer and BioNTech said they can customize their mRNA vaccine within six weeks and start shipping within 100 days if an escape variant is identified.

Johnson & Johnson on Friday said they are already testing their vaccine against Omicron.

“We are closely monitoring newly emerging COVID-19 virus strains with variations of the SARS-CoV-2 spike protein and are already testing the effectiveness of our vaccine against the new and rapidly spreading variant, which was first discovered in southern Africa,” said J&J .

AstraZeneca said the variant is also being investigated. Its vaccine platform, developed with Oxford University, enables rapid response to new mutations as they occur, the company said.

“AstraZeneca is also doing research in places where the variant has been identified, namely in Botswana and Eswatini,” the company said.

Modern, said in a statement on Friday that the combination of mutations in the variant “poses a significant potential risk of accelerating the decline in natural and vaccine-induced immunity”.

“A booster dose of an approved vaccine is the only strategy currently available to boost declining immunity,” the company said.

Moderna said it would test three booster candidates against Omicron, also in higher doses. The company will also develop a booster dose specific to the variant.

“We have said from the start that it is imperative that we be proactive in fighting the pandemic as the virus evolves,” said Stephane Bancel, CEO of Moderna, in a statement. “The mutations in the Omicron variant are worrying and for several days we have been working as quickly as possible to implement our strategy to combat this variant.”

The variant that originated in South Africa has around 50 mutations, more than 30 of which are on the spike protein, which enables the virus to bind to human cells. The spread of the new variant is still in its infancy, and it is not yet clear how difficult it would be to infect a vaccinated person.

Several European and Asian nations have suspended flights from southern Africa in response to the variant. The UK suspended flights from six countries in the region on Thursday and the European Commission – the executive body of the European Union – has asked all 27 member states to suspend travel from southern Africa.

White House senior medical advisor Dr. Anthony Fauci said Friday that the US is working with South African scientists to determine the molecular makeup of the variant so that laboratory tests can be carried out. These tests would help determine whether or not the variant can evade the vaccines’ antibody protection.

Fauci said data would help determine whether or not the US should put in place similar travel restrictions. The Biden government later confirmed Friday that the US would restrict entry to non-citizens from eight South African nations.

The strength of Covid vaccines against infection has decreased over time, although they are still highly effective at preventing hospitalizations and deaths. A study published in Science this month found that the Pfizer vaccine’s effectiveness in preventing infections decreased from 86% to 43% from February through October. Moderna’s vaccine decreased from 89% to 58% and J & J’s vaccine decreased from 86% to 13% effectiveness against infections in the same study.

The US Centers for Disease Control and Prevention last Friday approved booster vaccines of Pfizer-BioNTech and Moderna vaccines for all adults. Pfizer’s booster dose was 95% effective in preventing symptomatic infection in people who had no evidence of previous infection in a clinical study of 10,000 subjects 16 years and older, the company said. Moderna is still conducting a clinical study on the effectiveness of its booster dose.

Moderna says its Covid vaccine generates sturdy immune response in children 6 to 11

With husband Stephen by her side, Erin Shih hugs her children Avery 6 and Aidan 11 after receiving their second Moderna COVID-19 vaccines at Kaiser Permanente Los Angeles Medical Center on Friday, June 25, 2021.

Sarah Reingewirtz | MediaNews Group | Getty Images

Modern said Monday that in a study of children ages 6-11, a smaller dose of its Covid-19 vaccine is safe and produces a strong immune response.

Two 50-microgram doses of the vaccine, half the dose given in adults, resulted in antibody levels 1.5 times higher than in young adults, the company said in a press release, citing early data from a phase 2 / 3 study.

The syringes were generally well tolerated even in young children, according to the company, with the most common side effects being fatigue, headache, fever, and pain at the injection site. The vaccine has been tested on more than 4,700 children.

Moderna plans to submit the data to the Food and Drug Administration, the European Medicines Agency and other health authorities “in the near future”.

“We look forward to filing with regulators worldwide and remain committed to doing our part in ending the COVID-19 pandemic with a vaccine for adults and children of all ages,” said Stephane Bancel, CEO of Moderna, in a statement.

The new data comes the day before an important FDA advisory committee meeting to discuss whether to make a recommendation Pfizer and BioNTech‘s vaccine for children ages 5 to 11. The FDA could approve the vaccinations within days of the meeting, and the Centers for Disease Control and Prevention could approve them as soon as next week.

FDA staff said late Friday that Pfizer’s vaccine appears to be highly effective in preventing symptomatic infections in primary school children.

Many parents say they are careful to get their children vaccinated as the kids are entering the new school year and the Delta variant is still spilling across America. The number of new Covid cases in children remains exceptionally high with more than 1.1 million new child cases in the past six weeks, according to the American Academy of Pediatrics.

Covid vaccine boosters are actually out there. This is who’s eligible for Pfizer, Moderna and J&J’s pictures

A patient receives on 29.

Emily Elconin | Reuters

Nearly 100 million people across the country are immediately entitled to a Covid booster vaccination after the Centers for Disease Control and Prevention has additional doses of. have approved Modern and Johnson & Johnson‘s vaccines Thursday night.

The agency’s decision also allows fully immunized individuals to combine their booster vaccinations with doses from different manufacturers after research by the National Institutes of Health showed that combining and combining vaccines was safe and effective. Pfizer and BioNTech‘s boosters were largely released for use in the United States on September 24th.

About 11.6 million people across the country have already received their boosters, and CDC approvals have opened them up to tens of millions more people. But not everyone is eligible. Here’s who gets the extra doses in the U.S. based on their first round of shooting:

Pfizer-BioNTech

More than 47 million Pfizer vaccine recipients who received both vaccinations at least six months ago were eligible for a booster on Friday, according to data presented to the CDC’s advisory committee on Thursday. This contains:

  • Everyone who is 65 and older.
  • All adults between the ages of 18 and 64 who have cancer, dementia, diabetes, heart disease, HIV, and other conditions that make Covid complications more likely.
  • Anyone over the age of 18 who live or work in a long-term care facility, homeless shelter and prison or other community facility.
  • Frontline workers aged 18 and over who are at higher risk of Covid exposure due to their work, including first responders, teachers, supermarket workers and local transit workers.

Modern

According to the CDC presentation, more than 39.1 million Moderna vaccine recipients who received both vaccinations at least six months ago were able to receive a booster on Friday. The CDC has adopted the same criteria for Moderna recipients as Pfizer, as the two companies use the same mRNA technology in their Covid vaccines. They include.

  • Everyone who is 65 and older.
  • All adults between the ages of 18 and 64 who have cancer, dementia, diabetes, heart disease, HIV, and other conditions that make Covid complications more likely.
  • Anyone over the age of 18 who live or work in a long-term care facility, homeless shelter and prison or other community facility.
  • Frontline workers aged 18 and over who are at higher risk of Covid exposure due to their work, including first responders, teachers, supermarket workers and local transit workers.

Johnson & Johnson

The CDC has adopted slightly different criteria for J & J’s one-time Covid vaccine, making nearly 13 million recipients eligible as of Friday. This contains

  • All adults who were vaccinated with J & J’s Covid vaccine at least two months ago, instead of Pfizer and Moderna six months ago.
  • All adult J&J recipients are entitled to a booster vaccination, even if they do not have any underlying medical conditions or work or live in an occupation where there is a higher risk of Covid.

Snap, Intel, Moderna, Digital World Acquisition Corp and extra

Check out the companies that are making the headlines in midday trading.

Snap Snap stock slumped 26.6% after it released its quarterly results, which included both a drop in sales and a profit blow. The social media company said its advertising business had declined due to Apple’s privacy changes.

Facebook, TwitterSocial media and digital promotional stocks have gone down Based on Snap’s findings on the impact of Apple’s privacy changes. Facebook shares were down 5.5% and Twitter shares were down 4.8%.

Intel – Intel shares fell after a. 11.7% after weaker than expected sales report. The semiconductor company blamed an industry-wide chip shortage for its lost revenue and warned that its gross margin and free cash flow would decline over the next two to three years.

Modern – Shares in the biotech company fell 3.8% Deutsche Bank started coverage of Moderna with a sell rating. The company said potential innovations were already priced into Moderna’s stock. “We agree that there is potential to disrupt the dynamics in the broader realm of infectious viral diseases (e.g. influenza), but all of this is more than generously reflected in a rating that appears detached from a problematic assessment of reality “said German.

Digital World Acquisition Corp. – Shares of the SPAC, which make the planned social media platform of the former President Donald Trump public, skyrocketed again in the roller coaster trade. The blank check company, which trades on the Nasdaq under the ticker DWAC, shot up 216% at times and closed 107%. The stock rose more than 350% on Thursday due to its explosive trading volume and volatility.

Honeywell Honeywell’s shares are down 3.2% after the company lowered its full-year revenue forecast. The company also reported quarterly revenue that was below analysts’ expectations for the third quarter. However, the result exceeded the forecasts.

American Express American Express stocks rose 5.4% after the company beat earnings expectations. The company reported earnings of $ 2.27 per share on sales of $ 10.93 billion. Analysts polled by Refinitiv expected earnings of $ 1.80 per share on sales of $ 10.52 billion.

Urban Outfitters Urban Outfitters’ shares rose 1.5% after Citi upgraded the clothing retailer from neutral to buy. “We can’t ignore the -25% better risk / reward ratio in stocks since URBN’s 2nd quarter (reported August),” said Citi.

VF Corp. – The clothing company’s shares fell 4.5% after missing the top and bottom lines of quarterly results. VF Corp. reported earnings of $ 1.11 per share on sales of $ 3.2 billion. Wall Street expected earnings of $ 1.15 per share on sales of $ 3.5 billion, according to Refinitiv.

Seagate – Seagate shares rose 6.1% after the data storage company beat earnings estimates. The company reported earnings of $ 2.35 per share, 13 cents more than expected, according to Refinitiv. Seagate also outperformed revenue estimates and issued strong revenue and earnings per share projections for the current quarter.

Chipotle Mexican Grill – Chipotle shares fell 2.8% despite one Make a profit. The fast-casual chain has dashed analysts’ expectations, expecting adjusted earnings of $ 7.02 per share versus $ 6.32 per share, according to Refinitiv. Higher menu prices helped the company offset higher input costs.

Boston beer Boston Beer shares were up 1.6% on the brewery’s third-quarter sales report. Boston Beer had sales of $ 561.6 million, according to StreetAccount, beating analysts’ consensus estimate of $ 531.5 billion.

Whirlpool Whirlpool shares rose 2.7% after the home appliance maker beat Wall Street expectations for earnings per share. The company reported earnings of $ 6.68 per share, 56 cents more than Refinitiv’s consensus estimate.

Mattel Mattel shares rose 0.6% after the toy maker’s quarterly report beat analysts’ expectations. Mattel posted earnings of 84 cents per share on sales of $ 1.76 billion, while analysts polled by Refinitiv expected earnings of 72 cents per share on sales of 1.69 billion US dollars.

– CNBC’s Tanaya Macheel, Maggie Fitzgerald and Yun Li contributed to the coverage

FDA panel unanimously recommends Moderna Covid booster pictures for at-risk adults

A key advisory committee to the Food and Drug Administration unanimously recommended Thursday that booster shots be taken from ModernCovid-19 vaccine for people 65 and older and other Americans at risk. The vote was a critical step before the US can begin giving third vaccinations to some of the more than 69 million people who originally received this vaccine.

The non-binding decision of the Advisory Committee on Vaccines and Allied Biological Products of the FDA would extend the guidelines for Moderna with the third recordings of the FDA PfizerBioNTech Vaccination. These recordings were authorized less than a month ago to a wide range of Americans, including the elderly, adults with pre-existing medical conditions, and those who work or live in high-risk environments such as healthcare and grocery stores.

Although the agency has not always followed the advice of its committee, it often does. A final FDA decision on Moderna boosters could be made within days. A CDC Vaccines Advisory Committee is then expected to vote on the FDA’s proposal next week. If it recommends approval and the CDC endorses it, eligible Americans who completed their vaccinations at least six months ago could begin booster vaccinations immediately.

Booster vaccination has been a controversial issue for scientists – inside and outside of government – especially since many people in the US and other parts of the world have not yet received a single dose of a vaccine. The World Health Organization is urging wealthy countries to wait before distributing boosters, and some scientists say they are not convinced that most Americans need boosters right now.

When the FDA committee met last month, they opposed a proposal to distribute booster vaccines from Pfizer and BioNTech to the general public. Some committee members said at the time they were concerned that there wasn’t enough data to make a recommendation, while others argued that third shots should be restricted to specific groups.

After Moderna’s unanimous vote on Thursday, committee member Dr. Patrick Moore said the data the company submitted for approval of a booster was “not well explained,” adding that he was more on “gut instinct”.

“The data itself is not strong, but it is certainly going in a direction that supports this vote,” he said.

Some members said the boosters should prevent what they call breakthrough infections, which they believe are critical to protecting healthcare facilities from being overloaded, while other members said the third vaccinations should ensure high-risk patients don’t have serious illnesses. Some committee members also suggested that young people might not need boosters as the first few shots in these groups still persist.

Dr. Another member, Paul Offit, stressed that most people who received the first two doses of Moderna’s vaccine are still well protected and hopes the recommendation doesn’t send the “wrong message” to the public.

“If we’re trying to prevent the inevitable, which is a decline in neutralizing antibodies and an erosion of protection against mild or asymptomatic infections, that’s a high bar that we don’t hold any other vaccine by,” he told his colleagues.

The Biden government hopes the extra dose will provide long-term and permanent protection for the US population from serious illness, hospitalization, and death as the fast-paced Delta variant continues to spread.

Dr. Peter Marks, the FDA’s chief vaccine regulator, reached the committee Thursday before the vote, telling the panel of experts that the agency is promoting “all the different viewpoints” on the “complex and evolving” data.

“However, I would ask you, as we move forward, to do our best to focus our reflections on the science related to the proposal under consideration today and not on operational issues related to a booster campaign or related issues global vaccine justice. ”he added.

Moderna filed for FDA approval of a booster dose on September 1. The company said the results are based on a clinical study of about 170 adults, fewer than the 318 people screened for Pfizer’s booster vaccination. Moderna said a third half-dose shot – 50 micrograms – was safe for the first two injections and produced a strong immune response.

Once approved, the company plans to send a letter to health care providers explaining the dose difference for the third injection, said Dr. Jacqueline Miller, the company’s director of infection research, during a presentation Thursday.

The side effects of Moderna boosters were similar to those after the second dose, the company wrote in a document released Tuesday by the FDA. Most of the side effects were of minor severity and Moderna reported no cases of rare heart inflammation, myocarditis, or pericarditis in subjects for up to 29 days after receiving the booster.

Before recommending the third shots, the panel listened to several presentations, including from Israeli health officials, who began to offer boosters to their populations before many other countries. The country has mainly used Pfizer’s vaccine, but some Moderna boosters have been given.

Israel has given 3.7 million third vaccinations since its booster campaign began in late July, with about a third of the extra vaccinations going to people aged 60 and over, Sharon Alroy Price, director of public health at Israel’s Ministry of Health, told the panel.

She presented data suggesting that people receiving a booster dose are less likely to get infected with Covid or become seriously ill. She said officials have so far identified 17 cases of myocarditis or pericarditis after third doses.

“I think we can say, if we look at all of the data in Israel so far, that the use of booster doses has helped Israel reduce the infections and the severe cases,” she said.

– CNBC’s Robert Towey contributed to this report.

U.S. strikes nearer to clearing Moderna and J&J Covid booster photographs this week

Anjali Sundararaman, a student nurse at San Francisco State University, gives Cuixia Xu a dose of Moderna-COVID during a vaccination clinic at the Southeast Health Center in the Bayview-Hunters Point neighborhood of San Francisco, Calif. On Monday, February 24 19 vaccine. 8, 2021.

Stephen Lam | San Francisco Chronicle | Hearst Newspapers via Getty Images

Millions of Americans will be one step closer to getting a Covid-19 booster shot this week when a key Food and Drug Administration advisory panel meets on Thursday and Friday to discuss additional doses of the drug Modern and Johnson & Johnson Vaccinations.

The FDA’s Advisory Committee on Vaccines and Related Biological Products meets less than a month after US regulators authorized Covid booster recordings from Pfizer and BioNTechs Vaccine for a wide variety of Americans, including the elderly, adults with pre-existing conditions, and those who work or live in high-risk environments such as health and food workers.

More than 7 million Americans in the US received a booster dose as of Saturday, according to the latest data from the CDC.

Members on independent committees of the FDA and the Centers for Disease Control and Prevention said at the time they were frustrated that Pfizer recipients only entitled to get the extra shots, leaving out millions of Americans who got Moderna or J & J’s shots.

The FDA advisory group is due to discuss data on the safety and effectiveness of a Moderna booster in adults on Thursday. On Friday, the committee is expected to discuss J&J booster vaccinations for adults. The FDA could make a final decision within days of the meetings and pass it on to the CDC and its Vaccine Advisory Committee to make their own decision.

The CDC’s next vaccine advisory meeting is scheduled for October 20 through October 21, where the boosters are expected to be discussed.

The FDA meeting is based on the average daily Covid cases in the US fell below 100,000 last week more than 56% of the population are fully immunized against the virus and the pandemic is showing signs of easing. Getting vaccinated, getting booster shots, and avoiding large gatherings are crucial ways to mitigate a possible surge in cases over the holidays, according to health experts.

The Biden administration hopes that empowering the U.S. population will continue to provide long-term and lasting protection from serious illness, hospitalization, and death as the fast-paced Delta variant spreads.

The exposure led to an increase in hospital admissions in the US, mainly among the unvaccinated. Still, some vaccinated Americans have suffered what are known as breakthrough infections, and just over 19,000 of them – less than 1% – were hospitalized or died of Covid on Sept. 20, according to the CDC.

“Even with Delta, the current vaccines hold up reasonably well in terms of hospitalization and major illness,” said Norman Baylor, former director of the FDA’s vaccines office. “It’s the infections that seem to be a problem.”

Last month, Moderna said a third syringe at half the dose used for the first two injections was safe and produced a stronger immune response than that seen after the second dose in its phase III clinical trial .

J&J said last month that a second dose of its single vaccine was safe and increased protection against symptomatic infections from about 70% to 94% when given two months after the first dose in the US.

The FDA could approve Moderna and J&J booster syringes under the same criteria as Pfizer, or maybe change course and increase the number of Americans eligible for additional syringes, Baylor said in a telephone interview.

“The question is: does everyone need a booster now?” said Baylor, now president of the Biologics Consulting Group.

Committee members need to discuss whether it is safe and effective for J&J recipients to receive a second dose, Baylor said. He added that he did not expect any difficulty in getting third-dose approval of Moderna’s vaccine because it uses mRNA technology that was also used to develop Pfizer’s vaccines.

“If I was in my old position with the FDA, I probably wouldn’t have put Moderna on the advisory board because it’s in the same class as Pfizer,” he said.

Government communication on Pfizer booster vaccinations is already confusing and “very harmful” to public perception, said Dr. Isaac Bogoch, an infectious disease specialist at the University of Toronto.

“From the outside it looks a bit free for everyone,” said Bogoch. “Yeah, yeah, there are some loose guidelines in the United States. But basically it looks like anyone could go to any pharmacy and get a booster shot and say you know what I smoke or I’m obese or.” I work in healthcare. “

Shares making the largest strikes noon: Pfizer, Moderna, Boeing, extra

A Boeing 737 MAX 10 airliner stops while taxiing on the airline.

Stephen Brashear | Getty Images

Check out the companies that are making the headlines in midday trading.

Boeing – Boeing shares rose 3.2% after Virgin Orbit, a satellite launch spin-off from Sir Richard Branson’s Virgin Galactic, announced that it will go public at a valuation of $ 3.7 billion. Boeing will invest in the deal’s private investment in a public equity round. Virgin Orbit partners with a special purpose vehicle NextGen Acquisition Corp. II, which was up 1.9% on its shares after the news.

Pfizer, BioNTech – Drug manufacturers’ stocks rose Monday after the Food and Drug Administration full consent given to the Pfizer and BioNTech Covid-19 vaccine – first in the US to receive the coveted award. Pfizer’s shares rose 2.5% and BioNTech rose 9.6%. Shares in Modern rose 7.6% in the hope that approval paves the way for own approval.

General Motors – The automaker’s shares ticked 1.3% lower after General Motors’ Recall of his electric car Chevy Bolt on Friday. It will include newer models, a move that will cost the automaker an additional $ 1 billion. The recall addresses an issue that can increase the risk of battery fire.

Occidental Petroleum, Devonian energy – Energy stocks rebounded Oil prices rose on Monday, with a seven-day losing streak, the longest in crude oil since 2019. Occidental Petroleum rose 6.9%, Devon Energy rose 6.1%. Diamondback energy 5.9% increased and Marathon oil 5.4% up.

Robin Hood Robinhood stock rose 6.2% despite Wall Street analysts pessimistic on newly listed brokerage stocks. Many Cover initiated by investment firms was rated neutral or equal by Robinhood on Monday, and the stock was even given a rare underweight to JPMorgan’s Kenneth Worthington.

Didi Global – Chinese ride-hailing app shares rose 3.4% despite Beijing’s investigation into the company. The Financial Times reported Didi could be forced to sell shares with special rights to the Chinese government and the company could be asked to cut commissions from drivers.

Tesla – Tesla shares rose 3.8% after Deutsche Bank reiterated its purchase rating at the electric vehicle manufacturer. The company said Tesla’s Artificial Intelligence Day last week set out a “bold vision” and analysts “came with greater appreciation for it Tesla ‘s efforts on AI. “

Abercrombie & Fitch The apparel retail stock rose 2.3% after Tesley confirmed its outperformance rating from Abercrombie & Fitch and expected “margin widening”. The company plans to publish the results this week.

– CNBC’s Maggie Fitzgerald and Yun Li contributed to the coverage

Become a smarter investor with CNBC Pro.
Get stock picks, analyst calls, exclusive interviews and access to CNBC TV.
Sign in to get started Try it for free today